To include your compound in the COVID-19 Resource Center, submit it here.

Audentes gains on XLMTM readout

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $5.28 (15%) to $40.81 on Thursday after reporting interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE